Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast
May 07 2019 - 8:00AM
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s
health innovation, today announced that it will host a conference
call and live webcast at 4:30 p.m. Eastern
Time on Tuesday, May 14, 2019, to review the Company's
financial results for the quarter ended March 31, 2019 and to
provide a Company update.
To access the conference call via phone, dial
(844) 831-3031 (U.S.) or (765) 889-6776 (international). The
conference ID number for the call is 2297055. The live webcast can
be accessed under “Events & Presentations" in the Investor
Relations section of the Company's website
at www.darebioscience.com. Please log in approximately 5-10
minutes prior to the call to register and to download and install
any necessary software. To access the replay, please call (855)
859-2056 (U.S.) or (404) 537-3406 (international). The conference
ID number for the replay is 2297055. The call and webcast replay
will be available until May 21, 2019.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s sexual health, vaginal health,
fertility, and contraception. The company’s mission is to identify,
develop and bring to market a portfolio of novel, differentiated
therapies that expand treatment options, improve outcomes and
facilitate convenience for women in these targeted areas.
Daré’s product portfolio includes potential
first-in-class candidates in clinical development: Ovaprene®, a
non-hormonal, monthly contraceptive vaginal ring; Sildenafil Cream,
3.6%, a novel cream formulation of sildenafil to treat female
sexual arousal disorder utilizing the active ingredient in Viagra®;
DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2%
to treat bacterial vaginosis via a single application; and
DARE-HRT1, a combination bio-identical estradiol and progesterone
intravaginal ring for hormone replacement therapy following
menopause. To learn more about Daré’s full portfolio of women’s
health product candidates, and mission to deliver novel therapies
for women, please visit www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using its investor relations website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use
these channels to distribute material information about the
company, and may also use social media to communicate important
information about the company, its finances, product candidates,
clinical trials and other matters. The information Daré posts
on its investor relations website or through social media channels
may be deemed to be material information. Daré encourages
investors, the media, and others interested in the company to
review the information Daré posts on its investor relations
website (https://darebioscience.gcs-web.com/) and to follow
these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any
updates to the list of social media channels the company may use to
communicate information will be posted on the investor relations
page of the company's website mentioned above.
Contacts:
Investors on behalf of Daré Bioscience,
Inc.:
Alex GrayBurns
McClellanagray@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:
Jordann PhillipsCanale
CommunicationsJordann@canalecomm.com619-849-6009
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024